Ozempic-Like Drugs Linked to Rare Blindness Risk; Regulators Issue Urgent Eye Warning

Australia's Therapeutic Goods Administration (TGA) has issued a critical class-wide safety warning for popular GLP-1 Receptor Agonists (GLP-1 RAs), including Ozempic and Mounjaro, after linking them to a rare but severe eye disorder called Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION). This condition can cause sudden and potentially permanent vision loss, with 36 cases already reported in Australia connected to these widely used diabetes and weight-loss medications. The TGA alert, mirroring warnings from European regulators, highlights that while NAION is rare, it can lead to blindness and has no known treatment to restore vision once it occurs. Medications like Ozempic and Wegovy (containing semaglutide), Mounjaro (tirzepatide), and Saxenda (liraglutide) have been implicated, prompting updated product information documents for patients and healthcare professionals. This development adds a new dimension to ongoing scrutiny of GLP-1 RAs, which have revolutionized treatment for type 2 diabetes and obesity but come with various known side effects. Patients currently on GLP-1 RA medicines are strongly advised to seek urgent medical attention if they experience any sudden changes in vision. However, both the TGA and medical experts caution against discontinuing treatment without first consulting a doctor, emphasizing that the overall benefits of these drugs for managing chronic conditions remain significant and the risk of NAION is exceedingly low. Regulators will continue to monitor adverse events and evaluate the evolving evidence regarding these powerful pharmaceuticals.